Improved hematologic cancer survival in Europe over a 15 year period [EUROCARE-5 study]

1. Survival improved for most types of hematologic malignancies in Europe between 1992 and 2007. 

2. The improvements in survival for various malignancies were not geographically uniform throughout the European continent. 

Evidence Rating Level: 2 (Good) 

Study Rundown: Recent advancements in the treatment of hematologic malignancies, including the introduction of drugs such as rituximab, imatinib, and bortezomib, have changed the survival outlook for many patients. Prior to this study, there had been no large scale examinations of survival trends in patients with hematologic malignancies in Europe. The authors of this study set out to describe the 5-year survival for each different type of malignancy in addition to estimating the relative excess risk of death 5 years following diagnosis stratified by age, time period, and continental region. The study found an overall improvement in survival throughout the European continent. The improvements were not geographically uniform. This study benefited from the fact that patient data were drawn from large cancer registries, representing geographic regions as a whole rather than information gathered from individual centers of excellence. A drawback to this study is that little to no information was collected regarding confounding variables such as treatment type, stage of diagnosis, or comorbidities.

Click to read the study, published today in The Lancet Oncology

Relevant Reading: Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 a population-based study

In-Depth [retrospective cohort]: This study included 560,444 individuals greater than 15 years of age with hematologic malignancies from the EUROCARE-5 database between 1996 and 2007. Non-Hodgkin lymphoma was the most common malignancy (40.1%) followed next by myeloid malignancies (24.9%), multiple myeloma/plasmacytoma (15.0%), not otherwise specified (13.7%), and Hodgkin’s lymphoma (6.3%).

5-year survival increased significantly over the study period for all lymphoid malignancies with follicular lymphoma and large B-cell lymphoma having the largest increases, (58.9% [95% confidence interval, CI, 57.3-60.6] in 1997-99 to 74.3% [95% CI, 72.9-75.5] in 2006-08 and 29.8% [95% CI, 27.7-32.0] in 1997-99 to 41.1% (95% CI, 39.0-43.1) in 2006-08, respectively, p < 0.0001). Younger patients tended to have better 5-year survival than older patients as well as having a greater increase in survival over the study period.

More from this author: Vitamin D may reduce the risk of hypertension,Schizophrenia linked with higher rates of violence, suicide, and early mortality;Overall improvement in management of high blood pressure between 1994 and 2011;Link between early life antibiotic use, asthma exacerbations, and impaired viral immunity;Structural and neurobiological foundations of suicide, a review;Buccal administration of dextrose gel effective in treatment of neonatal hypoglycemia 

Image: PD 

©2012-2014 All rights reserved. No works may be reproduced without expressed written consent from Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.